GLP-1 Receptor Agonists

A structured evidence index of the incretin and amylin receptor agonist classes, navigable by endpoint, by trial phase and by receptor target.

Read this first

Every compound on this site is withheld from the index. All 17 of them are marked high impact in the corpus, none has a qualified clinical reviewer recorded against it, and the build will not publish a page that presents a withheld compound's evidence. Those pages are built, checked and served; they carry a noindex directive and they are absent from the sitemap.

This page, the method page and the editorial pages are publishable because they present no compound's evidence. They explain what exists and how it was assembled. They do not stand in for it.

What this site is for

A reference library is organised by compound: one page per substance, read one at a time. That is the wrong shape for a question like which members of a class carry a phase 3 record against renal endpoints, or which of them are recorded at more than one receptor. Answering that from an alphabetical index means opening seventeen pages and keeping the answer in your head.

So this site indexes the same corpus along three axes instead of one.

• By endpoint — six endpoints derived from the subject headings already on the records. One page per endpoint, a matrix of which compounds carry which class of record against it, every cell citing the records.
• By compound — the registered trial picture for one compound: counts by record class and study model, the years covered, the endpoints touched, and every record with its identifier.
• By receptor target — one target, and every compound in scope recorded as acting at it. The view a compound-by-compound reference cannot give.

Curated pairs read two compounds across all of those axes at once, and list the records indexed under both sides.

Scope

Two classes and nothing else: the incretin receptor agonists and the amylin analogues, 17 compounds in total. They are the only part of this corpus where the same endpoints are measured across many compounds by many separate trial programmes, which is what makes navigation by evidence mean anything. The rest of the corpus is not covered here and is not summarised here.

What is on this page and what is not

No per-compound record count, no trial phase, no endpoint coverage, no derived tier. Those are evidence and they sit behind the gate. The table above carries names, class and index state, which is navigation, and the figures beside the rail are totals for the whole scope, which describe the index rather than any compound in it.

For Research Use Only. Not for Human Consumption. The compounds described on this page are research chemicals. They are not approved by the FDA for human use. Nothing here is medical advice, a dosing protocol, or a recommendation to obtain or administer any substance.